Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. / Madsen, Martin K.; Fisher, Patrick M.; Burmester, Daniel; Dyssegaard, Agnete; Stenbæk, Dea S.; Kristiansen, Sara; Johansen, Sys S.; Lehel, Sczabolz; Linnet, Kristian; Svarer, Claus; Erritzoe, David; Ozenne, Brice; Knudsen, Gitte M.

I: Neuropsychopharmacology, Bind 44, 2019, s. 1328-1334.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Madsen, MK, Fisher, PM, Burmester, D, Dyssegaard, A, Stenbæk, DS, Kristiansen, S, Johansen, SS, Lehel, S, Linnet, K, Svarer, C, Erritzoe, D, Ozenne, B & Knudsen, GM 2019, 'Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels', Neuropsychopharmacology, bind 44, s. 1328-1334. https://doi.org/10.1038/s41386-019-0324-9

APA

Madsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., Erritzoe, D., Ozenne, B., & Knudsen, G. M. (2019). Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology, 44, 1328-1334. https://doi.org/10.1038/s41386-019-0324-9

Vancouver

Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbæk DS, Kristiansen S o.a. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019;44:1328-1334. https://doi.org/10.1038/s41386-019-0324-9

Author

Madsen, Martin K. ; Fisher, Patrick M. ; Burmester, Daniel ; Dyssegaard, Agnete ; Stenbæk, Dea S. ; Kristiansen, Sara ; Johansen, Sys S. ; Lehel, Sczabolz ; Linnet, Kristian ; Svarer, Claus ; Erritzoe, David ; Ozenne, Brice ; Knudsen, Gitte M. / Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. I: Neuropsychopharmacology. 2019 ; Bind 44. s. 1328-1334.

Bibtex

@article{391496c29df54f9cb6d324484c86b0e8,
title = "Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels",
abstract = "The main psychedelic component of magic mushrooms is psilocybin, which shows promise as a treatment for depression and other mental disorders. Psychedelic effects are believed to emerge through stimulation of serotonin 2A receptors (5-HT2ARs) by psilocybin{\textquoteright}s active metabolite, psilocin. We here report for the first time the relationship between intensity of psychedelic effects, cerebral 5-HT2AR occupancy and plasma levels of psilocin in humans. Eight healthy volunteers underwent positron emission tomography (PET) scans with the 5-HT2AR agonist radioligand [11C]Cimbi-36: one at baseline and one or two additional scans on the same day after a single oral intake of psilocybin (3–30 mg). 5-HT2AR occupancy was calculated as the percent change in cerebral 5-HT2AR binding relative to baseline. Subjective psychedelic intensity and plasma psilocin levels were measured during the scans. Relations between subjective intensity, 5-HT2AR occupancy, and plasma psilocin levels were modeled using non-linear regression. Psilocybin intake resulted in dose-related 5-HT2AR occupancies up to 72%; plasma psilocin levels and 5-HT2AR occupancy conformed to a single-site binding model. Subjective intensity was correlated with both 5-HT2AR occupancy and psilocin levels as well as questionnaire scores. We report for the first time that intake of psilocybin leads to significant 5-HT2AR occupancy in the human brain, and that both psilocin plasma levels and 5-HT2AR occupancy are closely associated with subjective intensity ratings, strongly supporting that stimulation of 5-HT2AR is a key determinant for the psychedelic experience. Important for clinical studies, psilocin time-concentration curves varied but psilocin levels were closely associated with psychedelic experience.",
author = "Madsen, {Martin K.} and Fisher, {Patrick M.} and Daniel Burmester and Agnete Dyssegaard and Stenb{\ae}k, {Dea S.} and Sara Kristiansen and Johansen, {Sys S.} and Sczabolz Lehel and Kristian Linnet and Claus Svarer and David Erritzoe and Brice Ozenne and Knudsen, {Gitte M.}",
note = "Correction to: Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels (Neuropsychopharmacology, (2019), 10.1038/s41386-019-0324-9)",
year = "2019",
doi = "10.1038/s41386-019-0324-9",
language = "English",
volume = "44",
pages = "1328--1334",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "nature publishing group",

}

RIS

TY - JOUR

T1 - Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels

AU - Madsen, Martin K.

AU - Fisher, Patrick M.

AU - Burmester, Daniel

AU - Dyssegaard, Agnete

AU - Stenbæk, Dea S.

AU - Kristiansen, Sara

AU - Johansen, Sys S.

AU - Lehel, Sczabolz

AU - Linnet, Kristian

AU - Svarer, Claus

AU - Erritzoe, David

AU - Ozenne, Brice

AU - Knudsen, Gitte M.

N1 - Correction to: Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels (Neuropsychopharmacology, (2019), 10.1038/s41386-019-0324-9)

PY - 2019

Y1 - 2019

N2 - The main psychedelic component of magic mushrooms is psilocybin, which shows promise as a treatment for depression and other mental disorders. Psychedelic effects are believed to emerge through stimulation of serotonin 2A receptors (5-HT2ARs) by psilocybin’s active metabolite, psilocin. We here report for the first time the relationship between intensity of psychedelic effects, cerebral 5-HT2AR occupancy and plasma levels of psilocin in humans. Eight healthy volunteers underwent positron emission tomography (PET) scans with the 5-HT2AR agonist radioligand [11C]Cimbi-36: one at baseline and one or two additional scans on the same day after a single oral intake of psilocybin (3–30 mg). 5-HT2AR occupancy was calculated as the percent change in cerebral 5-HT2AR binding relative to baseline. Subjective psychedelic intensity and plasma psilocin levels were measured during the scans. Relations between subjective intensity, 5-HT2AR occupancy, and plasma psilocin levels were modeled using non-linear regression. Psilocybin intake resulted in dose-related 5-HT2AR occupancies up to 72%; plasma psilocin levels and 5-HT2AR occupancy conformed to a single-site binding model. Subjective intensity was correlated with both 5-HT2AR occupancy and psilocin levels as well as questionnaire scores. We report for the first time that intake of psilocybin leads to significant 5-HT2AR occupancy in the human brain, and that both psilocin plasma levels and 5-HT2AR occupancy are closely associated with subjective intensity ratings, strongly supporting that stimulation of 5-HT2AR is a key determinant for the psychedelic experience. Important for clinical studies, psilocin time-concentration curves varied but psilocin levels were closely associated with psychedelic experience.

AB - The main psychedelic component of magic mushrooms is psilocybin, which shows promise as a treatment for depression and other mental disorders. Psychedelic effects are believed to emerge through stimulation of serotonin 2A receptors (5-HT2ARs) by psilocybin’s active metabolite, psilocin. We here report for the first time the relationship between intensity of psychedelic effects, cerebral 5-HT2AR occupancy and plasma levels of psilocin in humans. Eight healthy volunteers underwent positron emission tomography (PET) scans with the 5-HT2AR agonist radioligand [11C]Cimbi-36: one at baseline and one or two additional scans on the same day after a single oral intake of psilocybin (3–30 mg). 5-HT2AR occupancy was calculated as the percent change in cerebral 5-HT2AR binding relative to baseline. Subjective psychedelic intensity and plasma psilocin levels were measured during the scans. Relations between subjective intensity, 5-HT2AR occupancy, and plasma psilocin levels were modeled using non-linear regression. Psilocybin intake resulted in dose-related 5-HT2AR occupancies up to 72%; plasma psilocin levels and 5-HT2AR occupancy conformed to a single-site binding model. Subjective intensity was correlated with both 5-HT2AR occupancy and psilocin levels as well as questionnaire scores. We report for the first time that intake of psilocybin leads to significant 5-HT2AR occupancy in the human brain, and that both psilocin plasma levels and 5-HT2AR occupancy are closely associated with subjective intensity ratings, strongly supporting that stimulation of 5-HT2AR is a key determinant for the psychedelic experience. Important for clinical studies, psilocin time-concentration curves varied but psilocin levels were closely associated with psychedelic experience.

U2 - 10.1038/s41386-019-0324-9

DO - 10.1038/s41386-019-0324-9

M3 - Journal article

C2 - 30685771

AN - SCOPUS:85061199420

VL - 44

SP - 1328

EP - 1334

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

ER -

ID: 214302750